Agios Pharmaceuticals

Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so challenging. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At our core, we’re a biopharmaceutical company passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients. We’re a science-driven, patient-focused organization developing transformative therapies across three major focus areas: hematologic malignancies, solid tumors and rare genetic diseases. Patients are counting on us, and we’re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Our research engine continues to yield new insights and potential therapeutic approaches, growing our differentiated portfolio of preclinical, clinical and commercial programs. Through it all, we are propelled by our connections with one another and our shared goal of doing something extraordinary on behalf of those in need. Together, we can achieve the Other Side of Possible.